Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure

NCT00575952 is registered in ClinicalTrials.gov with Gynecologic Oncology Group as lead sponsor.

NCT NCT00575952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00575952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure
Lead sponsor
Gynecologic Oncology Group
Phase
Phase 1
Overall status
Completed
Start date
January 17, 2008
Completion date
July 16, 2016
Enrollment
27 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial adenosquamous carcinoma, endometrial clear cell adenocarcinoma, endometrial mixed adenocarcinoma, endometrial serous adenocarcinoma, endometrial squamous cell carcinoma, endometrial undifferentiated carcinoma, recurrent uterine corpus carcinoma, stage iiia uterine corpus cancer, stage iiic uterine corpus cancer, stage iva uterine corpus cancer, stage ivb uterine corpus cancer